Skip to main content
. 2020 Dec 3;41(1):6–16. doi: 10.1177/0333102420973994

Figure 3.

Figure 3.

Classification of attaining reversion from chronic migraine to episodic migraine (i.e. < 45 headache days per 12 weeks) during the OLTP in patients treated with erenumab who had reversion to episodic migraine at week 12 of the DBTP and who had complete monthly headache day data for the entire study period.

DBTP: double-blind treatment phase; OLTP: open-label treatment phase.

*After 24 weeks of erenumab treatment.

After 64 weeks of erenumab treatment.